Business Model & Revenue
Can-Fite Biopharma Ltd. (NASDAQ: CANF) is an Israeli clinical-stage biopharmaceutical company developing small molecule drugs targeting the A3 adenosine receptor. Founded in 2000 and headquartered in Petah Tikva, Israel.
Pipeline: Namodenoson (CF102) for pancreatic cancer (Phase 2a positive), NASH, and liver diseases. Piclidenoson (CF101) for autoimmune diseases — canine osteoarthritis (Phase 2 complete with Vetbiolix), human rheumatoid arthritis, and psoriasis.
Revenue: $410K from milestone payments, grants, and licensing fees. No product sales.
Financial Highlights
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.41M | $0.67M | $0.74M | $0.81M |
| Revenue Growth | -39.9% | -9.3% | -8.3% | -5.0% |
| Operating Income | ($9.95)M | ($8.13)M | ($8.20)M | ($10.10)M |
| Net Income | ($9.83)M | ($7.88)M | ($7.63)M | ($10.17)M |
Key Metrics
| Metric | Value |
|---|---|
| Market Cap | ~$20M |
| Cash (est.) | ~$5-10M |
| Pipeline | Namodenoson (Phase 2a pancreatic), Piclidenoson (Phase 2 canine) |
| Analyst Coverage | Wainwright ($65 PT) |
| Israeli HQ | Petah Tikva |
Competitive Landscape
Pancreatic cancer treatment is dominated by chemotherapy (Gemcitabine, FOLFIRINOX) with limited efficacy. Immunotherapy (Keytruda) works in only a small subset. Novel approaches include KRAS inhibitors (Amgen, Mirati) and stroma-targeting therapies. Namodenoson's A3 adenosine receptor approach targeting tumor microenvironment inflammation is differentiated.
Catalysts
-
Full Phase 2a pancreatic cancer data: Additional data presentations or publications could strengthen the signal.
-
Phase 2b initiation: Moving Namodenoson into a larger Phase 2b trial in pancreatic cancer would be a major de-risking event.
-
Pharma partnership: A licensing or co-development deal with a major oncology company (BMS, Merck, AstraZeneca) would validate the platform and provide capital.
-
Piclidenoson canine OA results: Vetbiolix JV Phase 2 data could generate milestone payments and veterinary market revenue.
-
NASH/liver disease data: Additional Phase 2 results in Namodenoson's other indications.
Key Risks
- Phase 2a signal in pancreatic cancer may not replicate in larger trials. Small sample sizes are unreliable.
- $410K revenue declining 40% YoY. The company has no product revenue.
- ($9.8M) annual loss. Capital raise almost certainly needed for Phase 2b/3.
- Israeli company with limited U.S. governance oversight. Foreign issuer disclosure requirements.
- Wainwright $65 PT is from a single small-firm analyst. Not a reliable valuation benchmark.
- Canine osteoarthritis program (Vetbiolix JV) has uncertain commercial value.
- Share capital increase and executive option grants proposed at May 28 AGM — dilution signals.
- Multiple indication programs spread resources thin across pancreatic cancer, NASH, liver disease, and autoimmune.
- No major pharma partnership or licensing deal. If the science works, partnerships would validate and fund development.
Our Thesis
Can-Fite's bull case centers on Namodenoson's Phase 2a pancreatic cancer data. Pancreatic cancer has a 5-year survival rate of ~12%, limited treatment options, and massive unmet need. Any oral drug showing disease stabilization or improvement in this setting would be a blockbuster.
The A3 adenosine receptor mechanism is novel and differentiated. Most cancer therapeutics target tyrosine kinases or immune checkpoints. Targeting the A3 adenosine receptor addresses inflammation and fibrosis in the tumor microenvironment — a complementary approach. If Namodenoson demonstrates meaningful efficacy in Phase 2b/3, the drug could be worth $500M-2B+ in peak annual sales.
At nano cap valuation, CANF is priced for failure. If Phase 2 data holds and Phase 3 begins, the stock could re-rate from ~$20M market cap to $100-300M. The Wainwright $65 price target implies $4B+ market cap — aggressive but not impossible if Namodenoson succeeds in pancreatic cancer.
The bear case: Phase 2a signals in small patient populations often don't replicate. Revenue is declining ($410K, -40%). The company needs cash for Phase 2b/3 — dilution is certain. Israeli biotechs have lower governance standards than U.S. companies. Wainwright's $65 PT from a single small-firm analyst is unreliable.
Speculative Buy for the asymmetric risk/reward.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.